vVARDIS announces pricing of Initial Public Offering at $18 per share

vVARDIS announces pricing of Initial Public Offering at $18 per share

Latest Medtech News


vVARDIS Holding AG, a Zug, Switzerland-based dental med-tech company, has priced its initial public offering of 9,722,223 Class A ordinary shares at $18.00 each, raising about $175 million before any over-allotment. Underwriters hold a 30-day option to buy up to 1,458,333 more shares at the offering price. The shares began trading on the New York Stock Exchange on November 13 under the symbol VVVV, and the offering was expected to close on or about November 16, subject to customary conditions. Goldman Sachs and J.P. Morgan are joint bookrunning managers, with William Blair, UBS Investment Bank and Deutsche Bank Securities as bookrunners.

As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.

The company, founded by dentists Haley and Goly Abivardi, markets the Curodont line, a drill-free approach to treating early-stage cavities. It reports that Curodont has treated more than 3.5 million teeth and is sold in more than 20,000 U.S. dental practices, and that Apollo Global Management made a minority investment earlier this year.

The offering priced below the $21 to $24 range the company had marketed, after it reduced the deal size earlier in the process.

For the broader MedTech space, a Swiss dental company listing in New York is uncommon. It also tests investor appetite for newly listed medical technology companies.

Go Back

We'd love to hear what you're building